Addex Pharmaceuticals appoints ceo

Bharatt Chowrira has a strong track record in biopharmaceutical industry

Addex Pharmaceuticals, a Swiss biopharmaceutical company pioneering allosteric modulation-based drug discovery and development, has appointed of Bharatt Chowrira as chief executive. Chowrira has a strong track record in the biopharmaceutical industry with more than 17 years of experience, combining research, licensing, corporate development, operations and legal expertise.

Chowrira joins Addex after serving at Nektar Therapeutics, a US biopharmaceutical company developing therapeutics based on advanced polymer conjugate chemistry, as senior vice president and chief operating officer until January this year.

Prior to Nektar, he was executive director, Worldwide Licensing & External Research at Merck & Co. He has also served as vice president of Sirna Therapeutics, a wholly owned subsidiary of Merck, where his responsibilities included strategic planning and licensing.

Addex has also dissolved its transition committee, which was led by Addex vice-chairman Vincent Lawton and included André Mueller and Ray Hill, director. The transition committee was set up as an interim measure following the departure of the former ceo. In addition, Mueller has reverted to the position of non-executive chairman.

You may also like

Research & Development

Addex moves R&D operations to Campus Biotech in Geneva

To advance its portfolio of allosteric modulator drug candidates
Research & Development

Addex cuts staff from 19 to 2 people

CEO Bharatt Chowira and executive management step down
Research & Development

Addex to cut 28 jobs at Geneva operation

This is a strategic move from a position of strength, says ceo
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Masters of synthesis

Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.
Research & Development

Addex makes job cuts to reduce costs

Restructures to focus on core r&d programmes and strategic partnerships
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer

The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Subscribe now